NeuroBo Pharmaceuticals, Inc. (NRBO)
NASDAQ: NRBO · IEX Real-Time Price · USD
4.460
-0.050 (-1.11%)
Jul 22, 2024, 9:54 AM EDT - Market open
NeuroBo Pharmaceuticals Employees
NeuroBo Pharmaceuticals had 8 employees as of December 31, 2023. The number of employees increased by 6 or 300.00% compared to the previous year.
Employees
8
Change (1Y)
6
Growth (1Y)
300.00%
Revenue / Employee
n/a
Profits / Employee
-$2,072,500
Market Cap
26.70M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8 | 6 | 300.00% |
| Dec 31, 2022 | 2 | -3 | -60.00% |
| Dec 31, 2021 | 5 | -2 | -28.57% |
| Dec 31, 2020 | 7 | -5 | -41.67% |
| Dec 31, 2019 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ATI Physical Therapy | 6,000 |
| Meihua International Medical Technologies Co. | 617 |
| Trinity Biotech | 380 |
| Accelerate Diagnostics | 134 |
| Beyond Air | 107 |
| Renalytix | 102 |
| SAB Biotherapeutics | 57 |
| Autonomix Medical | 8 |
NRBO News
- 11 days ago - NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July - PRNewsWire
- 26 days ago - NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity - PRNewsWire
- 26 days ago - NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - PRNewsWire
- 4 weeks ago - NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - PRNewsWire
- 4 weeks ago - NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models - PRNewsWire
- 2 months ago - NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone - PRNewsWire
- 2 months ago - NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June - PRNewsWire